# A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma

> **NCT01936389** · PHASE2 · COMPLETED · sponsor: **Robert Ritch, MD, LLC.** · enrollment: 10 (actual)

## Conditions studied

- Exfoliation Syndrome
- Ocular Hypertension
- Open Angle Glaucoma

## Interventions

- **DRUG:** AR-12286

## Key facts

- **NCT ID:** NCT01936389
- **Lead sponsor:** Robert Ritch, MD, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01936389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01936389, "A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01936389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*